Please use this identifier to cite or link to this item: https://doi.org/10.1111/ijlh.13691
Title: Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials
Authors: Chen, Yan-Ting
Valent, Erik T
van Beers, Erik H
Kuiper, Rowan
Oliva, Stefania
Haferlach, Torsten
Chng, Wee-Joo 
van Vliet, Martin H
Sonneveld, Pieter
Larocca, Alessandra
Keywords: Science & Technology
Life Sciences & Biomedicine
Hematology
gene expression profiling
multiple myeloma
prognostication
INTERNATIONAL STAGING SYSTEM
STEM-CELL TRANSPLANTATION
MOLECULAR CLASSIFICATION
SKY92
MAINTENANCE
ELIGIBILITY
VALIDATION
INDUCTION
IMPACT
FISH
Issue Date: 26-Aug-2021
Publisher: WILEY
Citation: Chen, Yan-Ting, Valent, Erik T, van Beers, Erik H, Kuiper, Rowan, Oliva, Stefania, Haferlach, Torsten, Chng, Wee-Joo, van Vliet, Martin H, Sonneveld, Pieter, Larocca, Alessandra (2021-08-26). Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY 44 (1) : 127-134. ScholarBank@NUS Repository. https://doi.org/10.1111/ijlh.13691
Abstract: Objectives: Typically, prognostic capability of gene expression profiling (GEP) is studied in the context of clinical trials, for which 50%-80% of patients are not eligible, possibly limiting the generalizability of findings to routine practice. Here, we evaluate GEP analysis outside clinical trials, aiming to improve clinical risk assessment of multiple myeloma (MM) patients. Methods: A total of 155 bone marrow samples from MM patients were collected from which RNA was analyzed by microarray. Sixteen previously developed GEP-based markers were evaluated, combined with survival data, and studied using Cox proportional hazard regression. Results: Gene expression profiling-based markers SKY92 and the PR-cluster were shown to be independent prognostic factors for survival, with hazard ratios and 95% confidence interval of 3.6 [2.0-6.8] (P <.001) and 5.8 [2.7-12.7] (P <.01) for overall survival (OS). A multivariate model proved only SKY92 and the PR-cluster to be independent prognostic factors compared to cytogenetic high-risk patients, the International Staging System (ISS), and revised ISS. A substantial number of high-risk individuals could be further identified when SKY92 was added to the cytogenetic, ISS, or R-ISS. In the cytogenetic standard-risk group, ISS I/II, and R-ISS I/II, 13%, 23%, and 23% of patients with adverse survivals were identified. Conclusions: For the first time, this study confirmed the prognostic value of GEP markers outside clinical trials. Conventional prognostic models to define high-risk MM are improved by the incorporation of GEP markers.
Source Title: INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
URI: https://scholarbank.nus.edu.sg/handle/10635/234470
ISSN: 1751-5521
1751-553X
DOI: 10.1111/ijlh.13691
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outsid.pdf1.37 MBAdobe PDF

OPEN

PublishedView/Download

SCOPUSTM   
Citations

2
checked on Jan 22, 2023

Page view(s)

17
checked on Jan 26, 2023

Download(s)

1
checked on Jan 26, 2023

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.